GLP1R and diabetes mellitus: Thus, this subgroup is likely to benefit from enhanced monitoring and support and the early use of diabetes/disease-modifying drugs (DMDs), such as sodium glucose co-transporter type 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA), which are prognosis-changing agents [40].